Gebruikswaardeonderzoek Alstroemeria : resultaten 1999-2000

In het kader van het gebruikswaardeonderzoek Alstroemeria vindt een regelmatige beoordeling van nieuwe cultivars plaats. De waarde voor de teler, de handel en de consument van deze nieuwigheden wordt vastgesteld door kwalitatieve en kwantitatieve eigenschappen te bepalen in een opplanting op een praktijkbeórijf, waarbij deze rassen worden vergeleken met een bekend referentieras. Daarnaast vindt in verschillende seizoenen houdbaarheidsonderzoek plaats in de uitbloeiruimte van het PP&O. In de periode december 1998 tot en met december 2000 werden 16 Alstroemeria-cultivars getoetst op hun gebruikswaarde voor de teler, handel en consument. Dit verslag beschrijft de gevolgde werkwijze en de resultaten van deze proef. De waardering van de rassen komt tot uitdrukking in de rasbeschrijving. Bij de interpretatie van de resultaten dient men rekening te houden met de beschreven teeltomstandigheden. Toepassen van een ander temperatuurregime, teelt op substraat, geen gebruik van grondkoefing, toepassing van dagver/ertg/ng, assimilatiebelichting of een ander bemestingsniveau kan de expressie van de eigenschappen beïnvloeden. fn dît rapport worden de gegevens verkregen uit de teeltwaarnemingen en het houdbaarheidsonderzoek verwerkt tot een beschrijving en een kwalificatie per cultivar

Sortimentsvergelijking saintpaulia ; verwerking van de resultaten 1999-2000

Het Praktijkonderzoek Plant en Omgeving heeft in samenwerking met de NTS-commissie Saintpaulia, een onderzoek uitgevoerd naar de invloed van de herkomst (teeltbedrijf) op de kwaliteit van het sortiment Saintpaulia. Hieruit is gebleken dat de smetgevoeligheid van Saintpaulia per ras en per herkomst verschilt. De raseffecten waren echter duidelijk groter dan de herkomsteffecten. De interactie tussen ras en herkomst was gering. Een ras dat weinig smetgevoelig was, bleek bij alle herkomsten als weinig smetgevoelig naar voren te komen. Smetgevoelige rassen kwamen bij de meeste herkomsten als smetgevoelig naar voren. Naar aanleiding van dit onderzoek is de verwachting dat bij een sortimentsopplanting op een ander bedrijf de verschillen in smetgevoeligheid tussen de rassen niet sterk zal veranderen. Wel zal hoogstwaarschijnlijk het niveau van smetgevoeligheid hoger dan wel lager kunnen liggen. De sortimentsvergelijking kon dus op één bedrijf blijven plaatsvinden

Current knowledge on biomarkers for contact sensitization and allergic contact dermatitis.

Contact sensitization is common and affects up to 20% of the general population. The clinical manifestation of contact sensitization is allergic contact dermatitis. This is a clinical expression that is sometimes difficult to distinguish from other types of dermatitis, for example irritant and atopic dermatitis. Several studies have examined the pathogenesis and severity of allergic contact dermatitis by measuring the absence or presence of various biomarkers. In this review, we provide a non-systematic overview of biomarkers that have been studied in allergic contact dermatitis. These include genetic variations and mutations, inflammatory mediators, alarmins, proteases, immunoproteomics, lipids, natural moisturizing factors, tight junctions, and antimicrobial peptides. We conclude that, despite the enormous amount of data, convincing specific biomarkers for allergic contact dermatitis are yet to be described

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12–14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus over the definition of the core domain of long-term control and how to measure it and (ii) to prioritize future areas of research for the measurement of the core domain of quality of life (QoL) in children. Moderated whole-group and small-group consensus discussions were informed by presentations of qualitative studies, systematic reviews and validation studies. Small-group allocations were performed a priori to ensure that each group included different stakeholders from a variety of geographical regions. Anonymous whole-group voting was carried out using handheld electronic voting pads according to predefined consensus rules. It was agreed by consensus that the long-term control domain should include signs, symptoms, quality of life and a patient global instrument. The group agreed that itch intensity should be measured when assessing long-term control of eczema in addition to the frequency of itch captured by the symptoms domain. There was no recommendation of an instrument for the core outcome domain of quality of life in children, but existing instruments were assessed for face validity and feasibility, and future work that will facilitate the recommendation of an instrument was agreed upon. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international group working together to develop a core outcome set (COS) for clinical trials in eczema (synonymous with atopic eczema and atopic dermatitis). HOME is coordinated from the Centre of Evidence Based Dermatology, University of Nottingham, U.K. Participation in HOME is open to anyone with an interest in outcomes for eczema. A COS is the agreed upon minimum set of instruments that should be included in all clinical trials for a particular condition. Use of a COS does not preclude using other instruments; other domains and instruments can also be included to meet the specific requirements of individual trials. COS initiatives are active across many fields of medicine and should enable better synthesis of trial data and reduce selective outcome reporting bias. The HOME initiative follows the best current guidance on developing a COS. Four core domains have been identified: clinician-reported signs; patient-reported symptoms; quality of life; and long-term control. The core outcome measurement instruments for clinician-reported signs and patient-reported symptoms have been established: the Eczema Area and Severity Index (EASI) for measuring clinician reported signs was agreed on at the HOME III meeting, and the Patient-Oriented Eczema Measure (POEM) was chosen to measure patient-reported symptoms at the HOME IV meeting. This is a report from the fifth consensus meeting of the HOME initiative (HOME V), which was held on 12–14 June 2017 in Nantes, France. The local organizers were Sebastien Barbarot and Jean-Francois Stalder of Nantes University Hospital, France

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms

The contribution of J. K. Lowry (1942–2021) to amphipod systematics: new and revisionary taxonomy

James K. Lowry (1942–2021) was one of the most prolific crustacean taxonomists of the late 20th through early 21st century, authoring some 214 publications over a period of some 55 years in which he named some 800 new taxa including 5 suborders, 62 families, 129 genera, and 548 species of primarily amphipod crustaceans. The present work provides a complete list of Jim Lowry’s scientific publications along with the new taxa that he described therein